These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 16193207)

  • 1. Continuous intravenous administration of a low dose of epoprostenol greatly decreased serum concentrations of endothelin-1 in primary pulmonary hypertension--a case report.
    Kakinuma Y; Honma S; Morimoto T; Maruyama H; Yamazaki A; Ishimitsu T; Yamaguchi I
    Angiology; 2005; 56(5):641-5. PubMed ID: 16193207
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endothelin-1 across the lung circulation in patients with pulmonary arterial hypertension and influence of epoprostenol infusion.
    Selimovic N; Andersson B; Bergh CH; Sakiniene E; Carlsten H; Rundqvist B
    J Heart Lung Transplant; 2009 Aug; 28(8):808-14. PubMed ID: 19632577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Continuous infusion of epoprostenol improves the net balance between pulmonary endothelin-1 clearance and release in primary pulmonary hypertension.
    Langleben D; Barst RJ; Badesch D; Groves BM; Tapson VF; Murali S; Bourge RC; Ettinger N; Shalit E; Clayton LM; Jöbsis MM; Blackburn SD; Crow JW; Stewart DJ; Long W
    Circulation; 1999 Jun; 99(25):3266-71. PubMed ID: 10385501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of continuous intravenous epoprostenol therapy on advanced primary pulmonary hypertension in Taiwanese patients.
    Hsu HH; Chen JS; Kuo SH; Chiang FT; Ko WJ; Kuo SW; Huang SC; Lee YC
    J Formos Med Assoc; 2005 Jan; 104(1):60-3. PubMed ID: 15660181
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma brain natriuretic peptide as a parameter to assess efficacy of continuous intravenous infusion of prostacyclin (epoprostenol) to treat severe primary pulmonary hypertension: a case report.
    Wakaumi M; Shiga T; Nozaki K; Fujiu K; Shimaya K; Ishizuka N; Matsuda N; Kasanuki H
    Heart Vessels; 2000; 15(3):144-6. PubMed ID: 11289503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Moderate-term effect of epoprostenol on severe portopulmonary hypertension.
    Kato H; Katori T; Nakamura Y; Kawarasaki H
    Pediatr Cardiol; 2003; 24(1):50-3. PubMed ID: 12574979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravenous and inhaled epoprostenol for primary pulmonary hypertension during pregnancy and delivery.
    Bildirici I; Shumway JB
    Obstet Gynecol; 2004 May; 103(5 Pt 2):1102-5. PubMed ID: 15121623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy.
    McLaughlin VV; Shillington A; Rich S
    Circulation; 2002 Sep; 106(12):1477-82. PubMed ID: 12234951
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of transition from intravenous epoprostenol to oral/inhaled targeted pulmonary arterial hypertension therapy in pediatric idiopathic and familial pulmonary arterial hypertension.
    Melnick L; Barst RJ; Rowan CA; Kerstein D; Rosenzweig EB
    Am J Cardiol; 2010 May; 105(10):1485-9. PubMed ID: 20451700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epoprostenol (prostacyclin) therapy in HIV-associated pulmonary hypertension.
    Aguilar RV; Farber HW
    Am J Respir Crit Care Med; 2000 Nov; 162(5):1846-50. PubMed ID: 11069824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival.
    Sitbon O; Humbert M; Nunes H; Parent F; Garcia G; Hervé P; Rainisio M; Simonneau G
    J Am Coll Cardiol; 2002 Aug; 40(4):780-8. PubMed ID: 12204511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous epoprostenol in inoperable chronic thromboembolic pulmonary hypertension.
    Cabrol S; Souza R; Jais X; Fadel E; Ali RH; Humbert M; Dartevelle P; Simonneau G; Sitbon O
    J Heart Lung Transplant; 2007 Apr; 26(4):357-62. PubMed ID: 17403477
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High plasma serotonin levels in primary pulmonary hypertension. Effect of long-term epoprostenol (prostacyclin) therapy.
    Kéreveur A; Callebert J; Humbert M; Hervé P; Simonneau G; Launay JM; Drouet L
    Arterioscler Thromb Vasc Biol; 2000 Oct; 20(10):2233-9. PubMed ID: 11031209
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of switching from epoprostenol to IV treprostinil on treatment satisfaction and quality of life in patients with pulmonary hypertension.
    Minai OA; Parambil J; Dweik RA; Davila GH; Peterson L; Rollins KD; Chen H
    Respir Med; 2013 Mar; 107(3):458-65. PubMed ID: 23266038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intrapulmonary shunting in primary pulmonary hypertension: an observation in two patients treated with epoprostenol sodium.
    Castro PF; Bourge RC; McGiffin DC; Benza RL; Fan P; Pinkard NB; McGoon MD
    Chest; 1998 Jul; 114(1):334-6. PubMed ID: 9674493
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pregnancy and primary pulmonary hypertension : successful outcome with epoprostenol therapy.
    Stewart R; Tuazon D; Olson G; Duarte AG
    Chest; 2001 Mar; 119(3):973-5. PubMed ID: 11243988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Current status and future prospect of prostacyclin therapy for pulmonary hypertension--intravenous, subcutaneous, inhaled and oral PGI2 derivatives].
    Saji T; Nakayama T; Ishikita T; Matsuura H
    Nihon Rinsho; 2001 Jun; 59(6):1132-8. PubMed ID: 11411125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Continuous intravenous epoprostenol in pulmonary hypertension: the Israel experience.
    Bendayan D; Fink G; Aravot D; Ygla M; Bendov I; Bliden L; Nir A; Kramer MR
    Isr Med Assoc J; 2002 Apr; 4(4):255-8. PubMed ID: 12001697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical study on long-term treatment of primary pulmonary hypertension with continuous intravenous epoprostenol infusion].
    Cao TS; Yuan LJ; Duan YY; Wang ZJ; Zhuang L; Shapiro SM; Brundage BH
    Zhonghua Nei Ke Za Zhi; 2003 Feb; 42(2):106-9. PubMed ID: 12783707
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improving Survival in Patients with Pulmonary Arterial Hypertension: Focus on Intravenous Epoprostenol.
    Demerouti E; Karyofyllis P; Manginas A; Anthi A; Karatasakis G; Athanassopoulos G; Voudris V
    Am J Cardiovasc Drugs; 2019 Apr; 19(2):99-105. PubMed ID: 30671881
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.